News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MRI Interventions, Inc. (MRIC) Release: Importance Of Real-Time MRI Guidance In Delivery Of Toca 511 Gene Therapy Directly To High Grade Glioma Presented At Annual Society For Neuro-Oncology Scientific Meeting


12/3/2013 9:13:37 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

IRVINE, Calif., Dec. 3, 2013 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) today announced the presentation of clinical data demonstrating the precision of MRI-guided delivery of the investigational gene therapy Toca 511 to high grade gliomas using the company's ClearPoint® Neuro Intervention System as the delivery platform. At the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology, held in conjunction with the 18th Annual Society for Neuro-Oncology Scientific Meeting and Education Day, Dr. Manish Aghi, neurosurgeon at University of California, San Francisco (UCSF), presented a poster showing interim data from an ongoing Phase I clinical trial evaluating the safety and tolerability of Toca 511 in combination with Toca FC in recurrent high grade glioma patients.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES